Literature DB >> 3930107

Assessment of biological activity of immunoglobulin preparations by using opsonized micro-organisms to stimulate neutrophil chemiluminescence.

C S Munro, P J Stanley, P J Cole.   

Abstract

We have used the ability of opsonised bacteria to stimulate luminol enhanced chemiluminescence of human neutrophils to examine the opsonic capabilities of normal and hypogammaglobulinaemic sera for four common bacterial pathogens. Preparations of human immunoglobulin modified for i.v. use have then been compared with unmodified Cohn Fraction II for their effectiveness in improving opsonization when added to antibody deficient sera in vitro. Hypogammaglobulinaemic sera exhibited impaired opsonisation of Haemophilus influenzae, and severely antibody deficient sera also opsonized Streptococcus pneumoniae and Pseudomonas aeruginosa poorly. The opsonization of these organisms was improved by Cohn Fraction II, and by pH 4 and beta-propionolactone treated immunoglobulins, in descending order of effectiveness. Pepsin digested immunoglobulin was inactive, and in some cases impaired opsonic capacity. The opsonisation of Staphylococcus aureus by hypogammaglobulinaemic sera was near normal, and was not improved by any immunoglobulin. This technique, which assesses biological activity of immunoglobulin, is useful in comparing preparations, and may help to establish appropriate dosage and frequency for intravenous immunoglobulin replacement therapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3930107      PMCID: PMC1577257     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  15 in total

1.  Haemophilus influenzae precipitins in the serum of patients with chronic bronchial disorders.

Authors:  M W Burns; J R May
Journal:  Lancet       Date:  1967-02-18       Impact factor: 79.321

2.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

3.  IgG subclasses in human gamma-globulin preparations for intravenous use and their reactivity with staphylococcus protein A.

Authors:  F Skvaril; B Roth-Wicky; S Barandun
Journal:  Vox Sang       Date:  1980       Impact factor: 2.144

4.  Intravenous immunoglobulin preparations.

Authors:  P Stanley; P Cole
Journal:  Lancet       Date:  1983-04-09       Impact factor: 79.321

5.  Factor affecting the in vitro assessment of opsonization: a study of the kinetics of opsonization using the technique of phagocytic chemiluminescence.

Authors:  A J Williams; M J Hastings; C S Easmon; P J Cole
Journal:  Immunology       Date:  1980-12       Impact factor: 7.397

6.  Influence of serum concentration on opsonization by the classical and alternative complement pathways.

Authors:  R W Tofte; P K Peterson; Y Kim; P G Quie
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

7.  Characterization of various immunoglobulin preparations for intravenous application. II. Complement activation and binding to staphylococcus protein A.

Authors:  J Römer; P J Späth; F Skvaril; U E Nydegger
Journal:  Vox Sang       Date:  1982-02       Impact factor: 2.144

8.  Characterization of various immunoglobulin preparations for intravenous application. I. Protein composition and antibody content.

Authors:  J Römer; J J Morgenthaler; R Scherz; F Skvaril
Journal:  Vox Sang       Date:  1982-02       Impact factor: 2.144

9.  Outer membrane protein composition in disease isolates of Haemophilus influenzae: pathogenic and epidemiological implications.

Authors:  M R Loeb; D H Smith
Journal:  Infect Immun       Date:  1980-12       Impact factor: 3.441

10.  Contact-activated factors: contaminants of immunoglobulins preparations with coagulant and vasoactive properties.

Authors:  B M Alving; D L Tankersley; B L Mason; F Rossi; D L Aronson; J S Finlayson
Journal:  J Lab Clin Med       Date:  1980-08
View more
  5 in total

1.  Haemophilus influenzae type b opsonins of intravenous immunoglobulins.

Authors:  S Bender; S Hetherington
Journal:  J Clin Immunol       Date:  1987-11       Impact factor: 8.317

2.  Opsonic activity of a new intravenous immunoglobulin preparation: Pentaglobin compared with sandoglobulin.

Authors:  N D Garbett; C S Munro; P J Cole
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

3.  Comparison of the clinical efficacy and safety of an intramuscular and an intravenous immunoglobulin preparation for replacement therapy in idiopathic adult onset panhypogammaglobulinaemia.

Authors:  N D Garbett; D C Currie; P J Cole
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

Review 4.  An update on the use of immunoglobulin for the treatment of immunodeficiency disorders.

Authors:  Stephanie Albin; Charlotte Cunningham-Rundles
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

5.  Intravenous gammaglobulin for immunodeficiency: report from The European Group for Immunodeficiencies (EGID).

Authors: 
Journal:  Clin Exp Immunol       Date:  1986-09       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.